Komori
Rohto Pharmaceutical (4527) · PolicyIncrease in long-term borrowings and decrease in cash on hand

Funding through cash on hand and undrawn loan commitments

First written in FY2021. 2 of 7 entries say "Restated". Latest entry: FY2027-H1.

7entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2021 – FY2027-H12021: 120212022: 020222023: 120232024: 220242025: 120252026: 22026
Same theme, other companies
Securing liquidity through commitment lines and other facilitiesA theme 441 companies write about · 52 as a headwind · 394 as a tailwind

54 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 447 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1Increase in long-term borrowings and decrease in cash on handAnnual report

    「This was mainly due to an increase of ¥1.5092 billion in long-term borrowings, while short-term borrowings decreased by ¥1.8978 billion, other current liabilities by ¥180.8 million and income taxes payable by ¥40.3 million.」

    After the large investment, the funding mix shifted toward higher long-term borrowings and lower short-term borrowings. Cash and cash equivalents decreased by ¥403.7 million from the end of the fiscal year.
  2. FY2026Increase in cash on hand and expansion of commitment facilitiesAnnual report

    「At the end of the current consolidated fiscal year, our group had cash and cash equivalents of ¥82.851 billion, and had also entered into overdraft agreements and loan commitment agreements totaling ¥22.308 billion with financial institutions to secure liquidity in emergencies, of which ¥20.978 billion remained undrawn.」

    Investment spending declined from the previous fiscal year, when the company made a large acquisition, and cash and cash equivalents recovered to ¥8.2851 billion. Total commitment facilities were ¥2.2308 billion, of which ¥2.0978 billion remained undrawn.
  3. FY2026-H1Decrease in investment spending and changes in the borrowing mix after the acquisitionAnnual report

    「Cash used in investing activities during the current interim consolidated accounting period was ¥652.2 million, a decrease of ¥7.7002 billion from the same period of the previous year. This was because the previous period included ¥7.4479 billion in expenditure for the acquisition of shares in a subsidiary resulting in a change in the scope of consolidation, whereas the current interim period included ¥523.4 million in expenditure for the acquisition of property, plant and equipment and ¥167 million in expenditure for the acquisition of investment securities, among other items.」

    Investment spending declined from the same period of the previous year, when the company made a large acquisition including Eu Yan Sang, and cash on hand increased during the current interim period. Meanwhile, short-term borrowings increased and long-term borrowings decreased.
  4. FY2025-H1Decrease in cash on hand and increase in borrowings following the acquisitionAnnual report

    「Cash used in investing activities during the current interim consolidated accounting period was ¥8.3525 billion, an increase of ¥7.5173 billion from the same period of the previous year. This was mainly due to ¥7.4479 billion in expenditure for the acquisition of shares in a subsidiary resulting in a change in the scope of consolidation.」

    The company spent ¥7.4479 billion to acquire a subsidiary, reducing cash and cash equivalents by ¥1.5691 billion from the end of the previous fiscal year. Meanwhile, it raised funds through increases in short- and long-term borrowings and contributions from non-controlling interests.
  5. FY2024RestatedAnnual report

    「At the end of the current consolidated fiscal year, our group had cash and cash equivalents of ¥86.562 billion, and had also entered into overdraft agreements and loan commitment agreements totaling ¥11.3 billion with financial institutions to secure liquidity in emergencies.」

    The company reaffirmed its funding policy of relying primarily on operating cash flow and cash on hand and using borrowings as necessary. Cash and cash equivalents increased from ¥7.7691 billion at the end of the previous fiscal year to ¥8.6562 billion.
  6. FY2023RestatedAnnual report

    「At the end of the current consolidated fiscal year, our group had cash and cash equivalents of ¥77.691 billion, and had also entered into loan commitment agreements totaling ¥11.364 billion with financial institutions to secure liquidity in emergencies.」

    The company reaffirmed its funding policy of relying primarily on operating cash flow and cash on hand and using borrowings as necessary. Cash and cash equivalents at period-end were ¥7.7691 billion, and undrawn loan commitments were ¥1.1364 billion.
  7. FY2021First statedAnnual report

    「The group generally funds working capital, capital investment and other requirements through cash flows from operating activities and cash on hand. When the scale of investment exceeds these sources, it raises funds through borrowings from financial institutions.」

    The company has identified, as an independent theme for the first time, its funding policy of covering working capital and capital investment with operating cash flow and cash on hand, and using borrowings when necessary. Cash and cash equivalents at period-end were ¥5.2254 billion, and undrawn loan commitments were ¥1.1294 billion.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.